By 2030, it is anticipated that the Romania Liver Cancer Therapeutics market will reach a value of $31.6 Mn from $8.5 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030. Liver Cancer Therapeutics in Romania is dominated by a few domestic pharmaceutical companies such as Biofarm, Antibiotice and Fundeni Clinical Institute. The Liver Cancer Therapeutics market in Romania is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Romania Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
The US obesity drugs market is projected to grow from $1.2 Bn in 2022 to $5.2 Bn by 2030, registering a CAGR of 20.3% during the forecast period of 2022-30. There is increasing awareness of the health risks associated with obesity, including heart disease, diabetes, and high blood pressure. This is driving demand for effective treatments that can help reduce the risk of these conditions. Novo Nordisk, a Danish pharmaceutical company is a major player in the obesity drugs market, with a portfolio of products that includes Saxenda (liraglutide), an injectable drug approved for weight loss in adults with obesity.
By 2030, it is anticipated that the Poland Liver Cancer Therapeutics market will reach a value of $64.1 Mn from $17 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030. Liver Cancer Therapeutics in Poland is dominated by a few domestic pharmaceutical companies such as Polpharma Biologics, Adamed Group and Celon Pharma. The Liver Cancer Therapeutics market in Poland is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Poland Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the Nigeria Liver Cancer Therapeutics market will reach a value of $10.3 Mn from $2.6 Mn in 2022, growing at a CAGR of 18.6 % during 2022-2030. Liver Cancer Therapeutics in Nigeria is dominated by a few domestic pharmaceutical companies such as Swiss Pharma Nigeria, Fidson Healthcare and Neimeth. The Liver Cancer Therapeutics market in Nigeria is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Nigeria Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
The US radiotherapy market is projected to grow from $2.9 Bn in 2022 to $3.97 Bn by 2030, registering a CAGR of 4% during the forecast period of 2022-30. The market is primarily driven by factors such as increasing cancer prevalence, rising demand for non-invasive cancer treatments, and technological advancements in radiotherapy equipment. The US is one of the largest markets for radiotherapy globally, with a significant number of cancer treatment centers and a high level of investment in research and development. The key players in the US radiotherapy market include major medical device manufacturers and radiation therapy providers such as Varian Medical Systems, Elekta AB, Accuray Incorporated, and Siemens Healthineers.
By 2030, it is anticipated that the Netherlands Liver Cancer Therapeutics market will reach a value of $28.8 Mn from $7.6 Mn in 2022, growing at a CAGR of 18.1 % during 2022-2030. The Liver Cancer Therapeutics in the Netherlands is dominated by a few domestic pharmaceutical companies such as AM-Pharma, Kiadis Pharma and Galapagos. The Liver Cancer Therapeutics market in the Netherlands is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Netherlands Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
The US liver disease therapeutics market is projected to grow from $9.7 Bn in 2022 to $13 Bn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-30. Liver diseases such as hepatitis, liver cancer, and NAFLD are becoming increasingly prevalent in the US population, driving demand for effective treatments. Some of the key players operating in the US liver disease therapeutics market include Gilead Sciences, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb, and Novartis AG. These companies are investing heavily in research and development to develop new and innovative treatments for liver disease and are expected to continue to drive the growth of the market in the coming years.
By 2030, it is anticipated that the Mexico Liver Cancer Therapeutics market will reach a value of $163.5 Mn from $44 Mn in 2022, growing at a CAGR of 17.9 % during 2022-2030. Liver Cancer Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Laboratorios PiSA, Liomont and Genomma Lab Internacional. The Liver Cancer Therapeutics market in Mexico is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Mexico Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
The US liver cancer therapeutics market is projected to grow from $1.2 Bn in 2022 to $3.9 Bn by 2030, registering a CAGR of 15.6% during the forecast period of 2022-30. The market for liver cancer therapeutics in the US is driven by factors such as the increasing prevalence of liver cancer, the growing demand for effective treatment options, and advancements in technology and drug development. In addition, the increasing use of combination therapies, the development of targeted therapies, and the focus on personalized medicine are also contributing to the growth of this market. The major players operating in the US liver cancer therapeutics market include pharmaceutical companies such as Bristol-Myers Squibb, Bayer Healthcare, Pfizer Inc., Eisai Co., Ltd., and F. Hoffmann-La Roche AG.
By 2030, it is anticipated that the Malaysia Liver Cancer Therapeutics market will reach a value of $17.5 Mn from $4.71 Mn in 2022, growing at a CAGR of 17.8% during 2022-2030. Liver Cancer Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga, Pantai Hospital and National Cancer Institute. The Liver Cancer Therapeutics market in Malaysia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Malaysia Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
By 2030, it is anticipated that the Kenya Liver Cancer Therapeutics market will reach a value of $8.1 Mn from $2.1 Mn in 2022, growing at a CAGR of 18.7 % during 2022-2030. Liver Cancer Therapeutics in Kenya is dominated by a few domestic pharmaceutical companies such as Cosmos Limited, Medisel and Hetero Labs. The Liver Cancer Therapeutics market in Kenya is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Kenya Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
The US infectious disease therapeutics market is projected to grow from $50.3 Bn in 2022 to $60.6 Bn by 2030, registering a CAGR of 2.35% during the forecast period of 2022-30. Antibiotics are one of the most commonly prescribed classes of drugs for infectious diseases, but the rise of antibiotic-resistant bacteria has led to the development of new antibiotics and alternative therapies, such as antivirals and antifungals. Gilead Sciences is a biopharmaceutical company that develops and markets therapeutics for infectious diseases, including HIV/AIDS, hepatitis B and C, and influenza.
By 2030, it is anticipated that the Italy Liver Disease Therapeutics market will reach a value of $831 Mn from $554 Mn in 2022, growing at a CAGR of 5.2% during 2022-2030. Liver Disease Therapeutics in Italy is dominated by a few domestic pharmaceutical companies such as Esaote, Chiesi Group, and Dompé. The Liver Disease Therapeutics market in Italy is segmented into different types of disease and different therapy types. Some of the major factors affecting the Italy Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
The US Oral Care market was valued at $14.8 Bn in 2022 and is estimated to expand at a CAGR of 4.2% from 2022 to 2030 and will reach $20.5 Bn in 2030. One of the main reasons propelling the growth of this market is increased awareness and an aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Koninklijke Philips N.V., Colgate-Palmolive Company, GlaxoSmithKline plc, Procter & Gamble, Johnson & Johnson, Unilever plc, Ultradent Products, Inc., 3M Company, Hain Celestial Group (Jason Natural Products, Inc.), Church & Dwight Co., Supersmile, and CloSYS among others.
The Canada Oral Care market was valued at $2.8 Bn in 2022 and is estimated to expand at a CAGR of 6.2% from 2022 to 2030 and will reach $4.5 Bn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Sun Pharmaceutical Industries, Altima Dental, Dental Solutions, Millenium Dental , Dentalcorp, 123Dentist among others.
The UK Oral Care market was valued at $916 Mn in 2022 and is estimated to expand at a CAGR of 4.2% from 2022 to 2030 and will reach $1273 Mn in 2030. One of the main reasons propelling the growth of this market is Rising Demand for Cosmetic Dentistry, Technological Advancements. The market is segmented by type, drug and distribution channel. Some key players in this market are Wisdom Toothbrushes, Curaprox UK, Oralieve, DenTek, Lush UltraDEX, Waken among others.
The Germany Oral Care market was valued at $1.29 Bn in 2022 and is estimated to expand at a CAGR of 4.4% from 2022 to 2030 and will reach $1.82 Bn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, Increasing prevalence of dental diseases. The market is segmented by type, drug and distribution channel. Some key players in this market are Elmex, Meridol, Dr. Best, Dontodent, blend-a-dent Biorepair, Odol-med3, Listerine, Kukident among others.
The France Oral Care market was valued at $969 Mn in 2022 and is estimated to expand at a CAGR of 5.2% from 2022 to 2030 and will reach $1453 Mn in 2030. One of the main reasons propelling the growth of this market is E-commerce Growth, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Pierre Fabre Oral Care, GUM, Laboratoires Septodont, Elgydium, Biotech Dental, 3M, Carestream Dental, Periosystem among others.
The Italy Oral Care market was valued at $846 Mn in 2022 and is estimated to expand at a CAGR of 5.7% from 2022 to 2030 and will reach $1317 Mn in 2030. One of the main reasons propelling the growth of this market is introduction of Increasing Demand for Natural and Organic Products, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are 3M, A-Dec Inc., Biolase Inc., Carestream Health Inc., Dentsply Sirona, and Envista Holdings Corporation among others.
The China Oral Care market was valued at $2.8 Bn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $5.1 Bn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Hawley & Hazel, Yunnan Baiyao Group, Shanghai Jahwa United Co, Guangzhou Lion Company, Fujian Sanli Group, Midmark, iByer Dental Group, Bybo Dental Group, ChengDu Huamei Dental Chain Co, Sirona Dental Systems, Foshan among others.
The Australia Oral Care market was valued at $423 Mn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $765 Mn in 2030. One of the main reasons propelling the growth of this market is Increasing Disposable Income, aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are White Glo, Grants of Australia, Red Seal, Dr. Brite, Pure Smile among others.
The UAE Oral Care market was valued at $176 Mn in 2022 and is estimated to expand at a CAGR of 7.2% from 2022 to 2030 and will reach $307 Mn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, Technological advancements. The market is segmented by type, drug and distribution channel. Some key players in this market are Dr. Michael's Dental Clinic, Dubai Smile Dental Center, Bin Arab Dental Center, Al Ain Dentistry Perfect, Smile Orthodontic and Cosmetic Dental Center, The dental studio among others.
The Egypt Oral Care market was valued at $99 Mn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $179 Mn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, a increasing urbanization. The market is segmented by type, drug and distribution channel. Some key players in this market are Marico Egypt, Amoun Pharmaceutical Company, Eva Pharma, Siwa Holding, Pharco Pharmaceuticals, among others.
The India Oral Care market was valued at $641 Mn in 2022 and is estimated to expand at a CAGR of 9.2% from 2022 to 2030 and will reach $1295 Mn in 2030. One of the main reasons propelling the growth of this market is Increasing urbanization, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Dabur India, Patanjali Ayurved, Colgate-Palmolive, Himalaya Wellness, Vicco Laboratories, Procter & Gamble, Baidyanath Ayurveda, Unilever among others.
The Spain Oral Care market was valued at $680 Mn in 2022 and is estimated to expand at a CAGR of 5.2% from 2022 to 2030 and will reach $1020 Mn in 2030. One of the main reasons propelling the growth of this market is Rising demand for premium oral care products, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are Vitaldent, Adeslas Dental, Sanitas Dental, Dentsply Sirona, BioHorizons, Kerr, GC Europe, Septodont, Sirona among others.